blood
Blood (blood)
Journal positioning
Blood is the flagship journal of the American Society of Hematology and the highest-impact hematology-specific journal in the world. It spans the full hematology spectrum — from clonal hematopoiesis, bone marrow biology, and coagulation mechanism through to clinical trials in leukemia, lymphoma, myeloma, sickle cell disease, and hemostasis disorders — with an unusual capacity to publish both fundamental mechanistic biology and definitive clinical trial evidence within one journal. The unifying editorial requirement is that work must speak to the hematology field broadly: a pure molecular biology paper without disease relevance, or a clinical trial in a non-hematologic cancer, does not belong here. The readership is the entire ASH membership: hematologists, hematologic oncologists, transfusion medicine specialists, and hematology researchers.
This skill is a fit / venue-selection / re-framing tool. It does not replace the journal's current official submission guidelines. Before submitting, re-check the live author instructions on the ASH / Blood platform.
When to trigger
- The author names Blood or the ASH as the target venue for a hematology or hematologic oncology manuscript.
- A paper on leukemia, lymphoma, myeloma, or benign hematology needs venue selection between Blood and other oncology or translational journals.
- A mechanistic hematopoiesis or coagulation study needs framing for the clinical relevance required at Blood.
- The author needs Blood's desk-reject risks and alternative-venue guidance before submitting.